Early and Sustained Remission after Treatment with Subcutaneously Administered Golimumab Is Associated with Normalized Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Post-hoc Analysis from PURSUIT Induction and Maintenance Trials
2013 ◽
Vol 108
◽
pp. S519
◽